Lilly out-licenses osteoarthritis candidate
This article was originally published in Scrip
Executive Summary
Canadian firm Transition Therapeutics has exclusively licensed worldwide rights to a novel small-molecule transcriptional regulator (TT-601) from Eli Lilly for the treatment of osteoarthritis pain. TT-601 has completed preclinical development and is slated to enter the clinic in the first half of 2014.